Results 151 to 160 of about 15,449 (239)

Successful Sequential and Additive Drug Challenge With Rapid Oral Desensitization in Rifampicin‐Induced Fever

Respirology Case Reports, Volume 14, Issue 5, May 2026.
We report a 63‐year‐old man with active pulmonary tuberculosis who developed drug‐induced fever after commencing standard anti‐TB therapy. Sequential and additive drug challenge identified rifampicin as the offending agent. The patient subsequently underwent successful rapid oral rifampicin desensitization in an outpatient setting, enabling completion ...
Xin Yue Guo, Constantine Zois
wiley   +1 more source

The scourge of ethambutol-related toxic optic neuropathy in the Philippines

Philippine Journal of Ophthalmology, 2010
‎
Richard C. Kho, MD
doaj  

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death

Cell Proliferation, Volume 59, Issue 5, May 2026.
This study identifies ferroptosis as a key driver of diabetes and its complications via iron metabolism and lipid peroxidation, elucidates organelle interactions underlying cell vulnerability, and provides insights for targeted therapies against metabolic disorders.
Zheng Wang, Ying Zhang, Yue Xu, Mengyuan Yang, Yuan Wei, Yuan Li, Tongyue Yang, Xu Wang, Chaona Yang, Qi Feng, Guolan Xing   +10 more
wiley   +1 more source

The electrophysiological characteristics of ethambutol toxic optic neuropathy

, 2023
Li S.
europepmc   +1 more source

Phase 2 trial of exercise and low‐dose ibuprofen for cancer‐related cognitive impairment in patients receiving chemotherapy

Cancer, Volume 132, Issue 8, 15 April 2026.
Abstract Background Interventions for cancer‐related cognitive impairment are understudied, particularly during therapy. Methods Patients with cancer receiving chemotherapy reporting cognitive problems were randomized to one of four study arms for 6 weeks in this phase 2 randomized controlled trial with a 2 × 2 factorial design.
Michelle C. Janelsins, Riham A. Alieldin, Tyler Holler, Hongying Sun, Po‐Ju Lin, Michelle Shayne, Alissa Huston, Kassandra Doyle, Michelle Porto, Mohamedtaki Tejani, Bryan Thompson, Allison Magnuson, Marcia Krebs, Richard F. Dunne, Supriya G. Mohile, Chin‐Shang Li, Umang Gada, Ajay Dhakal, Aram F. Hezel, Marcus S. Noel, Alok A. Khorana, Brian D. Yirinec, Nayana Kamath, David W. Dougherty, Tim A. Ahles, Gary R. Morrow, Karen M. Mustian   +26 more
wiley   +1 more source

Baseline Retinal Nerve Fiber Layer Thickness and Visual Outcomes of Eyes with Ethambutol Toxic Optic Neuropathy

Philippine Journal of Ophthalmology, 2018
Objectives: To determine the retinal nerve fiber layer thickness (RNFL) in eyes with ethambutol-induced toxic optic neuropathy (ETON) at the time of diagnosis and to describe the visual outcomes at 1, 3, and 6 months after discontinuation of ethambutol.
Franz Marie Cruz, MD, DPBO
doaj  

Choroidal Neovascularization and Toxic Optic Neuropathy Secondary to Tobacco Use: A Case Report. [PDF]

Cureus, 2020
Islam Y, Khurshid G.
europepmc   +1 more source

Cobalt toxic optic neuropathy and retinopathy: Case report and review of the literature. [PDF]

Am J Ophthalmol Case Rep, 2020
Garcia MD, Hur M, Chen JJ, Bhatti MT.
europepmc   +1 more source

Cisplatin-Induced Toxic Optic Neuropathy in a Patient With Hodgkin's Lymphoma. [PDF]

Cureus
Bee SY, Che Hamzah J, Nasaruddin RA, Naffi AA.   +3 more
europepmc   +1 more source